ReviewJournal of lipid and atherosclerosis2025
Triglycerides, Triglyceride-Rich Lipoproteins, and Remnant Cholesterol in Atherosclerotic Cardiovascular Disease.
Review in Journal of lipid and atherosclerosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE-Assessed Meta-Analysis of Randomized Trials With Trial Sequential Evidence.Endocrinology, diabetes & metabolism · 2026Pooled it
- Postharvest Aging and Harvest Stage Shape the Bioactive Profile, Hypolipidemic Activity, and Gut Microbiota-Modulating Effects of Citrus Peel Extracts in High-Fat-Diet-Fed Mice.Foods (Basel, Switzerland) · 2026Article
- The effect of pecan consumption on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2026Review
- Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.Translational and clinical pharmacology · 2026Article
- The cholesterol, high-density lipoprotein, and glucose (CHG) index as a novel metabolic marker for predicting adverse outcomes in myocardial infarction survivors: insights from two large prospective cohorts.Cardiovascular diabetology · 2026Article
- Triglyceride levels and all-cause mortality in patients with left main coronary artery disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2026Article
- Association between serum total cholesterol levels and the risk of incident heart failure in patients with atherosclerotic cardiovascular disease.Frontiers in medicine · 2026Article
- Predictors of Unfavorable Outcomes in Diabetic Foot Ulcers.Diagnostics (Basel, Switzerland) · 2025Article
- Beyond cardiovascular disease: remnant cholesterol as a novel risk factor for osteoarthritis.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The roles of triglycerides (TGs), triglyceride-rich lipoproteins (TRLs), and remnant cholesterol (RC) in cardiovascular disease have garnered increasing attention, particularly in light of the persistent residual cardiovascular risk that remains despite effective low-density lipoprotein cholesterol (LDL-C) management. Recent studies indicate that TGs and RC contribute to atherosclerosis independently of LDL-C. This review examines TG metabolism, the unique atherogenic properties of TRLs, and the mechanistic and clinical implications of RC in atherosclerosis. We critically evaluate whether TGs themselves are direct drivers of heart disease or whether the pathological effects arise mainly from TRL remnants and their cholesterol content. Furthermore, we review current and emerging therapeutic strategies targeting these lipid components and propose future directions for integrating TG and RC metrics into clinical risk management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.